FDA Accepts Ralinepag NDA for PAH, Sets June 2027 Decision Date
UTHR sits 70% above its 52-week low of $302.19.
Summary
The FDA accepted United Therapeutics' NDA for ralinepag, an oral prostacyclin receptor agonist for pulmonary arterial hypertension, with a PDUFA date of June 24, 2027. This is a major regulatory milestone for a drug that showed a 55% reduction in risk of clinical worsening in the phase 3 ADVANCE OUTCOMES trial. The acceptance follows the company's Q2 report where Nebulized Tyvaso sales fell 18%, making pipeline progress critical. Ralinepag's once-daily oral dosing could address a significant unmet need in PAH, though approval is still roughly 10 months away. The stock may react positively to the de-risking of the regulatory path, but the long timeline tempers immediate impact.
At the time of this announcement, UTHR was trading at $513.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22B. The 52-week trading range was $302.19 to $609.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.